Matches in DBpedia 2016-04 for { <http://wikidata.dbpedia.org/resource/Q5251502> ?p ?o }
Showing triples 1 to 58 of
58
with 100 triples per page.
- Q5251502 subject Q21571359.
- Q5251502 subject Q7139608.
- Q5251502 subject Q7364198.
- Q5251502 subject Q8297717.
- Q5251502 subject Q8357326.
- Q5251502 subject Q8872471.
- Q5251502 subject Q9052781.
- Q5251502 abstract "Deferasirox (marketed as Exjade, Desirox, Defrijet, Desifer...) is an oral iron chelator. Its main use is to reduce chronic iron overload in patients who are receiving long-term blood transfusions for conditions such as beta-thalassemia and other chronic anemias. It is the first oral medication approved in the USA for this purpose.It was approved by the United States Food and Drug Administration (FDA) in November 2005.According to FDA (May 2007), renal failure and cytopenias have been reported in patients receiving deferasirox oral suspension tablets. It is approved in the European Union by the European Medicines Agency (EMA) for children 6 years and older for chronic iron overload from repeated blood transfusions.".
- Q5251502 atcPrefix "V03".
- Q5251502 atcSuffix "AC03".
- Q5251502 bioavailability "70.0".
- Q5251502 casNumber "201530-41-8".
- Q5251502 drugbank "DB01609".
- Q5251502 fdaUniiCode "V8G4MOF2V9".
- Q5251502 iupacName "4-[(3Z,5E)-3,5-bis(6-oxo-1-cyclohexa-2,4-".
- Q5251502 iupacName "dienylidene)-1,2,4-triazolidin-1-yl]benzoic acid".
- Q5251502 pubchem "5493381".
- Q5251502 thumbnail Deferasirox.svg?width=300.
- Q5251502 wikiPageWikiLink Q1069061.
- Q5251502 wikiPageWikiLink Q10860654.
- Q5251502 wikiPageWikiLink Q130146.
- Q5251502 wikiPageWikiLink Q183605.
- Q5251502 wikiPageWikiLink Q185137.
- Q5251502 wikiPageWikiLink Q204711.
- Q5251502 wikiPageWikiLink Q21571359.
- Q5251502 wikiPageWikiLink Q246147.
- Q5251502 wikiPageWikiLink Q30.
- Q5251502 wikiPageWikiLink Q419618.
- Q5251502 wikiPageWikiLink Q458.
- Q5251502 wikiPageWikiLink Q476921.
- Q5251502 wikiPageWikiLink Q5445.
- Q5251502 wikiPageWikiLink Q677.
- Q5251502 wikiPageWikiLink Q7139608.
- Q5251502 wikiPageWikiLink Q7364198.
- Q5251502 wikiPageWikiLink Q749664.
- Q5251502 wikiPageWikiLink Q8297717.
- Q5251502 wikiPageWikiLink Q8357326.
- Q5251502 wikiPageWikiLink Q8872471.
- Q5251502 wikiPageWikiLink Q901125.
- Q5251502 wikiPageWikiLink Q9052781.
- Q5251502 wikiPageWikiLink Q9368.
- Q5251502 wikiPageWikiLink Q9377.
- Q5251502 atcPrefix "V03".
- Q5251502 atcSuffix "AC03".
- Q5251502 bioavailability "70.0".
- Q5251502 casNumber "201530".
- Q5251502 drugbank "DB01609".
- Q5251502 iupacName "4".
- Q5251502 pubchem "5493381".
- Q5251502 unii "V8G4MOF2V9".
- Q5251502 type ChemicalSubstance.
- Q5251502 type Drug.
- Q5251502 type ChemicalObject.
- Q5251502 type Thing.
- Q5251502 type Q8386.
- Q5251502 comment "Deferasirox (marketed as Exjade, Desirox, Defrijet, Desifer...) is an oral iron chelator. Its main use is to reduce chronic iron overload in patients who are receiving long-term blood transfusions for conditions such as beta-thalassemia and other chronic anemias.".
- Q5251502 label "Deferasirox".
- Q5251502 depiction Deferasirox.svg.